An Evaluation of Butoconazole Nitrate 2% Site Release® Vaginal Cream (Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis
Background. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2005-01-01
|
| Series: | Infectious Diseases in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2005/453239 |
| id |
doaj-3101f3612e7a4322826f942fd7068773 |
|---|---|
| record_format |
Article |
| spelling |
doaj-3101f3612e7a4322826f942fd70687732020-11-24T22:08:48ZengHindawi LimitedInfectious Diseases in Obstetrics and Gynecology1064-74491098-09972005-01-0113419720610.1155/2005/453239An Evaluation of Butoconazole Nitrate 2% Site Release® Vaginal Cream (Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal CandidiasisLarry S. Seidman0Campbell K. Skokos1Philadelphia Women's Research, 9501 Roosevelt Boulevard, Suite 404, Philadelphia, PA 19114, USAThe Women's Clinic, Little Rock, Arizona, AR, USABackground. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal candidiasis (VVC) with butoconazole nitrate 2% Site Release® vaginal cream (Gynazole-1®) and oral fluconazole 150 mg tablets (Diflucan®).http://dx.doi.org/10.1155/2005/453239 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Larry S. Seidman Campbell K. Skokos |
| spellingShingle |
Larry S. Seidman Campbell K. Skokos An Evaluation of Butoconazole Nitrate 2% Site Release® Vaginal Cream (Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis Infectious Diseases in Obstetrics and Gynecology |
| author_facet |
Larry S. Seidman Campbell K. Skokos |
| author_sort |
Larry S. Seidman |
| title |
An Evaluation of Butoconazole Nitrate 2% Site Release®
Vaginal Cream
(Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis |
| title_short |
An Evaluation of Butoconazole Nitrate 2% Site Release®
Vaginal Cream
(Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis |
| title_full |
An Evaluation of Butoconazole Nitrate 2% Site Release®
Vaginal Cream
(Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis |
| title_fullStr |
An Evaluation of Butoconazole Nitrate 2% Site Release®
Vaginal Cream
(Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis |
| title_full_unstemmed |
An Evaluation of Butoconazole Nitrate 2% Site Release®
Vaginal Cream
(Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis |
| title_sort |
evaluation of butoconazole nitrate 2% site release®
vaginal cream
(gynazole-1®) compared to fluconazole 150 mg tablets (diflucan®) in the time to relief of symptoms in patients with vulvovaginal candidiasis |
| publisher |
Hindawi Limited |
| series |
Infectious Diseases in Obstetrics and Gynecology |
| issn |
1064-7449 1098-0997 |
| publishDate |
2005-01-01 |
| description |
Background. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal candidiasis (VVC) with butoconazole nitrate 2% Site Release® vaginal cream (Gynazole-1®) and oral fluconazole 150 mg tablets (Diflucan®). |
| url |
http://dx.doi.org/10.1155/2005/453239 |
| work_keys_str_mv |
AT larrysseidman anevaluationofbutoconazolenitrate2sitereleasevaginalcreamgynazole1comparedtofluconazole150mgtabletsdiflucaninthetimetoreliefofsymptomsinpatientswithvulvovaginalcandidiasis AT campbellkskokos anevaluationofbutoconazolenitrate2sitereleasevaginalcreamgynazole1comparedtofluconazole150mgtabletsdiflucaninthetimetoreliefofsymptomsinpatientswithvulvovaginalcandidiasis AT larrysseidman evaluationofbutoconazolenitrate2sitereleasevaginalcreamgynazole1comparedtofluconazole150mgtabletsdiflucaninthetimetoreliefofsymptomsinpatientswithvulvovaginalcandidiasis AT campbellkskokos evaluationofbutoconazolenitrate2sitereleasevaginalcreamgynazole1comparedtofluconazole150mgtabletsdiflucaninthetimetoreliefofsymptomsinpatientswithvulvovaginalcandidiasis |
| _version_ |
1725814670190706688 |